A Novel Blood-based RNA Assay for Early Detection of Lethal Prostate Cancers
Technical Report,15 Sep 2018,14 Sep 2019
Cedars-Sinai Medical Center Los Angeles United States
Pagination or Media Count:
Our research collaborator, Dr. Michael Freeman CSMC has developed a new transcriptome-based subtyping Prostate Cancer Classification System PCS. PCS categorizes PCa into 3 subtypes which are related to survival, response to therapy and may even predict resistance to certain types of treatment. The limitation of these genomic assays, however, is the need for tissue biopsy. Given the risk and invasiveness of the procedure, a non-invasive assay with the reference to molecular features driving clinical behavior and outcomes would potentially address this unmet need in PCa. RNA-based molecular signatures can be detected in circulating tumor cells CTCs, making this an opportune way to further use of these evolving genomic signatures. While promising, this process requires improvement and further development before it can be used in the clinic. Over the past decade, our team has pioneered the NanoVelcro CTC assay, in which capture agent-coated nanosubstrates are used to selectively enrich CTCs. Recently, we have introduced the ThermoResponsive TR-NanoVelcro CTC purification assay, which allows capture and release of CTCs with intact RNA. This allows for seamless coupling with NanoString nCounterAregistered platform to accurately quantify the expression of RNA transcripts. Using these tools, our goal is to develop CTC-based PCS panel that will measure the aggressiveness of PCa. This tool could be used not only for early detection, but also for continuous monitoring of disease in response to treatment as serial blood collection is safe and easy. This allows for timely detection of emerging drug resistance and progression that will be of particular benefit to those patients with advanced mCRPC and their treating physicians.
- Medicine and Medical Research